Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

XRP44X, an Inhibitor of Ras/Erk Activation of the Transcription Factor Elk3, Inhibits Tumour Growth and Metastasis in Mice.

Semenchenko K, Wasylyk C, Cheung H, Tourrette Y, Maas P, Schalken JA, van der Pluijm G, Wasylyk B.

PLoS One. 2016 Jul 18;11(7):e0159531. doi: 10.1371/journal.pone.0159531. eCollection 2016.

2.

Human Papillomavirus-related tumours of the oropharynx display a lower tumour hypoxia signature.

Hanns E, Job S, Coliat P, Wasylyk C, Ramolu L, Pencreach E, Suarez-Carmona M, Herfs M, Ledrappier S, Macabre C, Abecassis J, Wasylyk B, Jung AC.

Oral Oncol. 2015 Sep;51(9):848-56. doi: 10.1016/j.oraloncology.2015.06.003. Epub 2015 Jun 27.

PMID:
26121938
3.

The oncogenic MicroRNA Hsa-miR-155-5p targets the transcription factor ELK3 and links it to the hypoxia response.

Robertson ED, Wasylyk C, Ye T, Jung AC, Wasylyk B.

PLoS One. 2014 Nov 17;9(11):e113050. doi: 10.1371/journal.pone.0113050. eCollection 2014.

4.

Elk3 deficiency causes transient impairment in post-natal retinal vascular development and formation of tortuous arteries in adult murine retinae.

Weinl C, Wasylyk C, Garcia Garrido M, Sothilingam V, Beck SC, Riehle H, Stritt C, Roux MJ, Seeliger MW, Wasylyk B, Nordheim A.

PLoS One. 2014 Sep 9;9(9):e107048. doi: 10.1371/journal.pone.0107048. eCollection 2014.

5.

Tubulin tyrosine ligase like 12, a TTLL family member with SET- and TTL-like domains and roles in histone and tubulin modifications and mitosis.

Brants J, Semenchenko K, Wasylyk C, Robert A, Carles A, Zambrano A, Pradeau-Aubreton K, Birck C, Schalken JA, Poch O, de Mey J, Wasylyk B.

PLoS One. 2012;7(12):e51258. doi: 10.1371/journal.pone.0051258. Epub 2012 Dec 12.

6.

ANO1 amplification and expression in HNSCC with a high propensity for future distant metastasis and its functions in HNSCC cell lines.

Ayoub C, Wasylyk C, Li Y, Thomas E, Marisa L, Robé A, Roux M, Abecassis J, de Reyniès A, Wasylyk B.

Br J Cancer. 2010 Aug 24;103(5):715-26. doi: 10.1038/sj.bjc.6605823. Epub 2010 Jul 27.

7.

The expression of ELK transcription factors in adult DRG: Novel isoforms, antisense transcripts and upregulation by nerve damage.

Kerr N, Pintzas A, Holmes F, Hobson SA, Pope R, Wallace M, Wasylyk C, Wasylyk B, Wynick D.

Mol Cell Neurosci. 2010 Jun;44(2):165-77. doi: 10.1016/j.mcn.2010.03.005. Epub 2010 Mar 18.

8.

Tubulin tyrosine ligase like 12 links to prostate cancer through tubulin posttranslational modification and chromosome ploidy.

Wasylyk C, Zambrano A, Zhao C, Brants J, Abecassis J, Schalken JA, Rogatsch H, Schaefer G, Pycha A, Klocker H, Wasylyk B.

Int J Cancer. 2010 Dec 1;127(11):2542-53. doi: 10.1002/ijc.25261.

9.

CTIP2 expression in human head and neck squamous cell carcinoma is linked to poorly differentiated tumor status.

Ganguli-Indra G, Wasylyk C, Liang X, Millon R, Leid M, Wasylyk B, Abecassis J, Indra AK.

PLoS One. 2009;4(4):e5367. doi: 10.1371/journal.pone.0005367. Epub 2009 Apr 28. Erratum in: PLoS One. 2009;4(4). doi: 10.1371/annotation/b01c646f-14c7-4aac-8812-9ed4f847c857. Indra, Arup [corrected to Indra, Arup K].

10.

Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays.

Rickman DS, Millon R, De Reynies A, Thomas E, Wasylyk C, Muller D, Abecassis J, Wasylyk B.

Oncogene. 2008 Nov 20;27(51):6607-22. doi: 10.1038/onc.2008.251. Epub 2008 Aug 4.

PMID:
18679425
11.

Inhibition of the Ras-Net (Elk-3) pathway by a novel pyrazole that affects microtubules.

Wasylyk C, Zheng H, Castell C, Debussche L, Multon MC, Wasylyk B.

Cancer Res. 2008 Mar 1;68(5):1275-83. doi: 10.1158/0008-5472.CAN-07-2674.

12.

Head and neck squamous cell carcinoma transcriptome analysis by comprehensive validated differential display.

Carles A, Millon R, Cromer A, Ganguli G, Lemaire F, Young J, Wasylyk C, Muller D, Schultz I, Rabouel Y, Dembélé D, Zhao C, Marchal P, Ducray C, Bracco L, Abecassis J, Poch O, Wasylyk B.

Oncogene. 2006 Mar 16;25(12):1821-31.

PMID:
16261155
13.
14.

Siah-1b is a direct transcriptional target of p53: identification of the functional p53 responsive element in the siah-1b promoter.

Fiucci G, Beaucourt S, Duflaut D, Lespagnol A, Stumptner-Cuvelette P, Géant A, Buchwalter G, Tuynder M, Susini L, Lassalle JM, Wasylyk C, Wasylyk B, Oren M, Amson R, Telerman A.

Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3510-5. Epub 2004 Feb 25.

15.

Differential expression profiling of head and neck squamous cell carcinoma (HNSCC).

Lemaire F, Millon R, Young J, Cromer A, Wasylyk C, Schultz I, Muller D, Marchal P, Zhao C, Melle D, Bracco L, Abecassis J, Wasylyk B.

Br J Cancer. 2003 Nov 17;89(10):1940-9.

16.

The transcription factor Net regulates the angiogenic switch.

Zheng H, Wasylyk C, Ayadi A, Abecassis J, Schalken JA, Rogatsch H, Wernert N, Maira SM, Multon MC, Wasylyk B.

Genes Dev. 2003 Sep 15;17(18):2283-97.

17.

Sp100 interacts with ETS-1 and stimulates its transcriptional activity.

Wasylyk C, Schlumberger SE, Criqui-Filipe P, Wasylyk B.

Mol Cell Biol. 2002 Apr;22(8):2687-702.

19.

p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53.

Wasylyk C, Salvi R, Argentini M, Dureuil C, Delumeau I, Abecassis J, Debussche L, Wasylyk B.

Oncogene. 1999 Mar 18;18(11):1921-34.

20.

Interaction of Ets-1 and the POU-homeodomain protein GHF-1/Pit-1 reconstitutes pituitary-specific gene expression.

Bradford AP, Wasylyk C, Wasylyk B, Gutierrez-Hartmann A.

Mol Cell Biol. 1997 Mar;17(3):1065-74.

21.

Conserved mechanisms of Ras regulation of evolutionary related transcription factors, Ets1 and Pointed P2.

Wasylyk C, Bradford AP, Gutierrez-Hartmann A, Wasylyk B.

Oncogene. 1997 Feb 27;14(8):899-913.

22.
23.

Reversion of Ras transformed cells by Ets transdominant mutants.

Wasylyk C, Maira SM, Sobieszczuk P, Wasylyk B.

Oncogene. 1994 Dec;9(12):3665-73.

PMID:
7970725
24.

Oncogenic conversion of Ets affects redox regulation in-vivo and in-vitro.

Wasylyk C, Wasylyk B.

Nucleic Acids Res. 1993 Feb 11;21(3):523-9.

25.

Oncogenic conversion alters the transcriptional properties of ets.

Wasylyk C, Wasylyk B.

Cell Growth Differ. 1992 Sep;3(9):617-25.

26.

A novel modulator domain of Ets transcription factors.

Wasylyk C, Kerckaert JP, Wasylyk B.

Genes Dev. 1992 Jun;6(6):965-74.

27.

Cell-specific regulation of oncogene-responsive sequences of the c-fos promoter.

Gutman A, Wasylyk C, Wasylyk B.

Mol Cell Biol. 1991 Oct;11(10):5381-7.

28.
29.

The c-ets proto-oncogenes encode transcription factors that cooperate with c-Fos and c-Jun for transcriptional activation.

Wasylyk B, Wasylyk C, Flores P, Begue A, Leprince D, Stehelin D.

Nature. 1990 Jul 12;346(6280):191-3.

PMID:
2114554
30.

Oncogene v-jun modulates DNA replication.

Wasylyk C, Schneikert J, Wasylyk B.

Oncogene. 1990 Jul;5(7):1055-8.

PMID:
2165232
31.

PEA3 is a nuclear target for transcription activation by non-nuclear oncogenes.

Wasylyk C, Flores P, Gutman A, Wasylyk B.

EMBO J. 1989 Nov;8(11):3371-8.

32.

Expression of raf oncogenes activates the PEA1 transcription factor motif.

Wasylyk C, Wasylyk B, Heidecker G, Huleihel M, Rapp UR.

Mol Cell Biol. 1989 May;9(5):2247-50.

33.
34.
35.

v-jun is a transcriptional activator, but not in all cell-lines.

Imler JL, Ugarte E, Wasylyk C, Wasylyk B.

Nucleic Acids Res. 1988 Apr 11;16(7):3005-12.

36.

A Harvey-ras responsive transcription element is also responsive to a tumour-promoter and to serum.

Imler JL, Schatz C, Wasylyk C, Chatton B, Wasylyk B.

Nature. 1988 Mar 17;332(6161):275-8.

PMID:
2831462
37.

Negative regulation contributes to tissue specificity of the immunoglobulin heavy-chain enhancer.

Imler JL, Lemaire C, Wasylyk C, Wasylyk B.

Mol Cell Biol. 1987 Jul;7(7):2558-67.

38.

The c-Ha-ras oncogene and a tumor promoter activate the polyoma virus enhancer.

Wasylyk C, Imler JL, Perez-Mutul J, Wasylyk B.

Cell. 1987 Feb 13;48(3):525-34.

PMID:
3026648
39.

B-lymphocyte targeting of gene expression in transgenic mice with the immunoglobulin heavy-chain enhancer.

Gerlinger P, LeMeur M, Irrmann C, Renard P, Wasylyk C, Wasylyk B.

Nucleic Acids Res. 1986 Aug 26;14(16):6565-77.

40.

The immunoglobulin heavy chain enhancer is stimulated by the adenovirus type 2 E1A products in mouse fibroblasts.

Borrelli E, Hen R, Wasylyk C, Wasylyk B, Chambon P.

Proc Natl Acad Sci U S A. 1986 May;83(9):2846-9.

42.

Short and long range activation by the SV40 enhancer.

Wasylyk B, Wasylyk C, Chambon P.

Nucleic Acids Res. 1984 Jul 25;12(14):5589-608.

43.

A novel eukaryotic promoter element: the simian virus 40 72 base pair repeat.

Wasylyk B, Wasylyk C, Chambon P.

Fed Proc. 1984 Feb;43(2):226-34.

PMID:
6319202
44.
45.

Transcription from the SV40 early-early and late-early overlapping promoters in the absence of DNA replication.

Wasylyk B, Wasylyk C, Matthes H, Wintzerith M, Chambon P.

EMBO J. 1983;2(9):1605-11.

46.

The conalbumin "TATA" box sequence and the SV40 72 base-pair repeat region influence expression of a chimeric gene in vivo.

Wasylyk B, Gaub MP, Dierich A, Wasylyk C, Chambon P.

Prog Clin Biol Res. 1982;85 Pt A:13-24. No abstract available.

PMID:
6287480

Supplemental Content

Loading ...
Support Center